We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Possible Pentostatin-Induced Symptomatic Hyponatremia.
- Authors
Bruno, Jeffrey J.; Canada, Todd W.
- Abstract
Pentostatin is an adenosine deaminase inhibitor used in the treatment of hairy cell leukemia and T-cell lymphomas. A 27-year-old man with refractory cutaneous T-cell lymphoma developed severe hyponatremia 3 days after completing his first cycle of pentostatin therapy. Shortly after hospital admission, he became disoriented and was admitted to the medical intensive care unit and treated with a combination of hypertonic saline, intravenous diuretics, and fluid restriction to reestablish normal sodium homeostasis. The mechanism by which pentostatin may have induced hyponatremia in this patient is unknown; clinical and laboratory findings represented both extrarenal sodium loss and syndrome of inappropriate antidiuretic hormone. Clinicians should be aware of the possible development of life-threatening symptomatic hyponatremia in patients receiving pentostatin.
- Subjects
LEUKEMIC reticuloendotheliosis treatment; ADENOSINE deaminase; STATINS (Cardiovascular agents); T cells; LYMPHOMAS; HYPONATREMIA; DRUG therapy; CANCER
- Publication
Pharmacotherapy, 2007, Vol 27, Issue 1, p164
- ISSN
0277-0008
- Publication type
Article
- DOI
10.1592/phco.27.1.164